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In the GISSI trial, 11,712 patients with acute myocardial
infarction were randomized to receive either standard
care or standard care with 1.5 million units streptokinase
intravenously. A highly significant reduction in mortality
during hospitalization in streptokinase-treated patients
was observed. The mortality at 1 year was determined
in 98.3% of the patients who had been originally ran-
domized; the 1 year mortality of patients discharged
alive was similar in those patients treated with strep-
tokinase and those who were not; that is, the beneficial
Over the last few years very large scale clinical trials have
been recognized as a uniquely powerful tool for assessing
the effectiveness of selected interventions on the natural
history of diseases whose origin and prognosis are known
to be multifactorial. Because of their complexity these clin-
ical conditions are, in fact, expected to be only partially
modified by any single treatment. The beneficial effects, if
they exist, are likely to be detected in only a small fraction
of patients by employing end points that may differ in their
clinical relevance and their duration. The large population
that must be recruited to test the statistical and clinical
significance of the effect of the intervention constitutes a
formidable organizational challenge. At the same time, a
large population has the advantage of allowing the gener-
ation of testable hypotheses in subgroups of patients.
The large scale study of the treatment of acute myocardial
infarction with streptokinase, conducted by the Gruppo
Italiano per la Sperimentazione della Streptochinasi nellIn-
farto Miocardico (G1SSI), is presented here as an example
of a trial providing answers to an important question in
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effects of streptokinase treatment on survival that were
observed in the hospital phase of the study persisted
unchanged and with comparable statistical significance
for 1 year. However, a higher incidence of reinfarction
occurred in the treated versus the control groups both
during the hospital phase and at the 6 month follow-up.
Streptokinase treatment had no detectable effect in pa-
tients with a history of previous infarction.
(J Am Coli Cardiol1987; 10:33B-98)
contemporary cardiology, while simultaneously generating
complementary information that may be useful for the un-
derstanding of acute myocardial infarction and for evalu-
ating and planning additional research. We summarize here
the short-term findings and present a preliminary analysis
of the intermediate and long-term results of the trial.
GISSI Study Protocol
The design and method of GISSI have been described in
detail previously (1). For the purpose of this presentation it
is useful to reemphasize some of the features of the study
protocol.
An open design was adopted, with no constraints on the
participating clinicians other than central randomization of
the eligible patients to either a streptokinase or a control
(no streptokinase) group. The patients entered into the trial
were managed according to the routine practice of eaeh
individual clinical setting, the only recommendation being
that the same attitude be adopted for the treated and control
groups. The well balanced distribution of the use of car-
diovascular drugs in the two groups that was found both in
the hospital phase and at the planned 6 month follow-up
documents the highly satisfactory compliance with the pro-
tocol by the investigators (Table 1), Accordingly, it appears
appropriate to discuss the principal and secondary findings
of the trial as depending solely on the fact that patients were
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Table I. Cardiovas cular Drugs Administered in the Coronary Care Unit (CCU ) and at
6 Month Follow -Up
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CCU 6-Month Follow-Up
(n = 11.712) (n '" 8,485)
SK ('Ii) C( %'f SK (%l C (%)
Anticoagulants 21.5 20. 8 7.Y 7.3
Calcium heparin 40.8 41.7 0.6 0.4
Antiplarelet agents 13.0 14.7 47.3 45.7
Antiarrhythmic agents 35.1) 34.0 u .o 14.1
Calcium channel antagonists 47.2 49.5 52.4 52.4
Beta-receptor blockers 8.3 8.3 11.3 11.3
Nitrates 68.1 71.9 44.0 44.9
C '" control group; SK = streptokinase-treated group.
or were not treated with J.5 million units of streptokinase
infused over 60 minutes.
The GISSI population can further be seen as a highly
representative sample of patients with acute myocardial in-
farction admitted routinely to a general coronary care unit,
because only about go/(; of the eligible patients were not
randomized for reasons not anticipated in the protocol. Data
were analyzed and are presented according to the intention
to treat principle, even though only 4% of the patients did
not receive the full assigned treatment because of interven-
ing complications. Finally. although a detailed follow-up
record at 6 months was available for only 72.4% of the
recruited patients (82.2% of those discharged alive). the
Patients admitted to CCU
with AMr




principal end point of mortality at I year has been assessed
for 98.3% of the originally randomizedpopulation (Fig. I) .
Results of the GISSI Trial
Mortality. Table 2 summarizes the results of the trial in
relation to the primary end point of in-hospital mortality.
the relative risk estimates have been divided into planned
(prospective) and data-derived (post hoc) findings, to com-
ply with the traditional rule that stratifications may give
information of varying reliability according to whether or
not they were linked prospectively to the hypothesis to be
tested.
Patients with complete data
I1.712 (9Y. I~~ of randomized)
-----------.
--.
10.326 Patients discharged alive
~.
Patients followed up -- -~ 8,485
at 6 months (82.2% of patients discharged alive)
hy CCUs
Patients followed up at
I year by coordinating
center
11.521
(98.3% of patients with complete data)
Figure 1. Diagram of the study of the Gruppo Ital iano
per 10 Studio della Streptochinasi nell'lnfarto (GISSI) .
AMI = acute myocardial infarction; CCU = coronary
care unit.
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Table 2. Relative Risk of Mortality at Year Assessed by Baseline Characteristics and
Prognostic Factors
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('I -xz confidence interval: RR = relative risk of mortality.
The overall results of the study population 4 ter the I
yearjollow-up are presen ted ill Figure 2. which documents
that the beneficial effect of streptokinase treatment persists
substantially unchanged and with comparable statistical sig-
nificance as in the hospital phase (p = 0.006). The I year
mortality of the patients discharged alive from the hospital
is presented in Table 3, which shows a striking similarity
between the treated and the control COh0l1S with respect to
life expectancy.
Clinical cardiac and cerebral events. The outcome of
the GISSI population with respect to clinically assessed
cardiac and cerebral events for the hospital phase and at the
6 month follow-up is shown in Table 4. Three clinical end
points showed important differences between the treated and
control cohorts in the acute hospital phase (reinfarction, left
ventricular failure and pericarditis), but only the reinlarction
rate revealed a persistent difference at 6 months. The low
rate of coronary bypass surgery and coronary angioplasty
(well balanced in the two cohorts) excludes any specific
influence of the procedures in determining the outcome.
Stroke appears to remain a treatment-independent event in
the follow-up period.
Discussion
Effect on early mortality. The principal conclusion de-
rived from the final results of the GlSSI trial is confirmation
that the benefit obtained in the acute phase of acute myo-
cardial infarction with a simple infusion of 1.5 million units
of streptokinase persists for at least I year. The questions
formulated in the first publication (2) appear to have been
answered decisively from the data presented here. They are
highly consistent with the hypothesis presented in the first
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Figure 2. Cumulati ve percent survival of the overa ll
population. C = control ; SK = streptokinase ,
o 2 4 6 8 10 12
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Table 3. Percent Mortality of Patients Discharged Alive in Relation to Baseline Character istics
and Prognostic Factors (mean follow-up 550 ± 136 days)
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7.7 (2 11 of 2.7 35)
9.1 ( 149 of 1.6291
11.6 (70 of 606)
8.6 (2 1 of 245)
5. 5 (197 of 3.607 )
1304 (16101' 1.201)
22.5 (94 of 417 )
14,2 (133 of 939)
7A (3 19 of 4.286)
6 .9 (304 of 4. 430)
1804 (142 of 770 )
8.7 (452 of 5.225)
Retrospectively Identified Subgroups
10 04 (189 of 1.822)
6 .3 (I ll of 1.869)
6 .7 ( 18 of 270)
7.8 (59 of 756)
19.1 (34 of 178)
10.0 (30 of 30 I)
6. \ (240 of 3,924)
14.9 (166 of 1.(1 5)
29.9 (38 of 127)
17.1 (7 of 41)
8.7 (452 of 5.225 )
C
( n =- 5.09 t)
7. 5 (203 of 2.7(9)
9 .6 (148 of 1.544)
11.1 (62 of 565)
8.8 (23 of 26 1)
6 .1 (21 2 of 3,494)
JI .5 (136 of 1.l79)
21 ,7 (90 of 415)
13.0 ( IJ6 of 893)
7.7 (322 of 4 ,197 )
6.9 (300 of 4,3 (8)
18.1 (134 of 74 1)
8.6 (438 of 5 ,091)
10.9 (194 of 1.787)
7.4 ( 137 of 1.859 )
7.4 (17 of 230)
6.0 (42 of 698)
12.6 (24 of 190)
7.8 (24 of 308)
6 .3 (239 of 3.806)
14 .1 (15 1 of 1.074)
26.2 (39 of 149)
12.5 (5 of 40)
8 .6 (438 of 5,09 1)
No statistically significant differences have been found in any of the reported subgroups. The differences
that may be observed with respect to some variables (for example, Killip4, ST t )are due to the small number
of patients involved and are far from any statistical significance. Abbreviations as in Tables 1 and 2.
lACC Vol. 10. No.5
November 1987:33B-9B
ROVELLI lOT AI..
GlSSl EARLY RESULTS AND LATE FOI.LOW·UP
37R
Table 4. Number of Patients With Major Clinical Events in the Hospital and at 6 Month Follow-Up
In-Hospital 6 Month Follow-Up
SK (%) C ('ii) RR SK ('if) C ('if) RR
(n = 5.S60) (n = 5)>52) (9S'.;i CII (n ~. 4.301 ) (n = 4.184) (95'!i CI)
Angina 846 (144) 903 (154) O.n 10S:~ 10 1.(2) 1.141 (26.5) LOSI (2S I) i.o: (0.7 to 1.18)
Reinfarction 232 (4.11) 122 (2.11 1.94 (1.55 to 2.41) 153 0.6) 105 (2.5) 1.43 (1.11 to l.85)
LVF 697 (119) SOO (137) (US 10.76 to 11.95) IS I 0.5) IS I n.6) O.Y7 (0.71 to UI)
Pericurditis 374 (6.4) 66S (11.4) 0.52 (0.46 to 11.60,
Stroke 63 (1. I) 54 (091 1.1 W.77 [(176) 30 W.7) 2x (0.7) 1.04 (047 lil 23.0X)
CABG 131 (3.0) lIS e.sl I.OS (.O.Sl to 1.43)
PICA II (lUI S lOll 1.34 (()3l 10 5.(0)
As is dear from the 95o/r confidence intervals (Cl) cnlcularcd for the relative risk (RRI esnmutcs. a stati-ticully significanr difference in the rrcqucncy
of events may be assumed to occur in the rates of reinlurction (both in the hospital phase and at 6 month follow-up I in luvur of the control (e) group.
left ventricular failure (LVF) and pericarditis Iin hospital events. in favor of the streptokinase ISKl-treuted patients). CABO ~ coronary artery bypass
graft: PTCA = percutaneous transluminal comnary angioplasty.
(hospital) phase of myocardial infarction have the same
prognosis whether or not they were treated with a throm-
bolytic agent (1).
Effect on long-term clinical course and prognosis. The
differences in the magnitude of the effects that were apparent
during the hospital phase for the various subgroups (Table
2) do not herald a different long-term prognosis. It was the
study's principal hypothesis that thrombolysis alone had to
be shown to be effective in order to be generally applicable
with no specific precautions, except those routinely applied
in any coronary care unit. In addition to its public health
implication, the affirmative answer provided by the study
suggests that early reopening of the infarct-related coronary
artery is decisive in determining outcome. Full anticoagu-
lation, traditionally considered a mandatory component of
thrombolytic therapy. was not the rule in the GISSI trial,
and no differences were found between the reinfarction rates
regardless of whether patients were treated with any of the
drugs that are deemed to affect the thromhotic process (3).
One findingdeserves particular attention: there was a higher
incidence of reocclusion in the treated versus the control
groups both during the hospital phase and at the 6 month
follow-up. However, reinfarction events did not appear to
be prognostic of mortality when patients with and without
such events were compared. No difference was found in the
treated and control groups in any of the other clinical events
determined at the 6 month follow-up (Table 4).
Role of previous myocardial infarction. Possibly the
most intriguing finding of the GISSI trial was the lack of
an effect of streptokinase treatment in patients with a prior
history of infarction. No satisfactory explanation is avail-
able, although the finding appears unlikely to he spurious
or biased. Each patient's history, together with age, sex and
time from onset of pain, was collected during the random-
ization telephone call made before the patient was assigned
to one group. Further. the number of GISSI patients with
a history of prior infarction is larger than the entire popu-
lation of other trials (3). It will be interesting to assess the
experience of the ISIS-2 trial (4) if the similar order of
magnitude of a beneficial effect found in the preliminary
analysis of one subgroup (patients treated <4 hours after
the onset of pain) is indicative of that in a population similar
to the one recruited into the GISSI trial.
Clinical implications. Unexpected findingsof very large
scale trials sometimes call for post hoc explanations of the
results (5,6). Suggestions or recommendations drawn from
subgroup analyses of smaller trials may be ingenious but
are difficult to interpret (7,8).
The specific strength of the GISSI experience is that it
provides a straightforward answer to the question of the
effect of thrombolysis on a largely unselected population of
patients with acute myocardial infarction that is represen-
tative of the potential recipients of this therapy. It will be
interesting to determine how the early systematic application
of more radical procedures such as coronary angioplasty and
coronary bypass surgery modifies the natural course of post-
acute myocardial infarction found in streptokinase-treated
patients in the GISSI trial.
Appendix
The following Clinical Centers participated:
Albano Laziale (G. Ruggeri. L. Giamundo, G. Montanari, P. Az-
zolini. L. Sunseri. G. L. Villa. T. Celeffi, I. Bisccgtia. G. Gallucci).
Ancona "Inrca" (E. Paciaroni, G. Saccomanno. L. Quattrini, C.
Gambini. A Andreoni. P. Bolognini, G. Urbano. M. Merli. M. Merli.
M. Franceschini. C. Ferroni, M. Marini).
Ancona "Landsi" (N. Ciampani, A. Purcaro. R. Ricciotti).
Andria (R. Antolini. R. Musaico)
Aosta (G. Devoti. M. De Marchi).
I\rezzo (M. Capone Braga).
Arienzo (V. Zueconelli. A. Iervoglini, M. Fierro. B. Castelli, C. De
Matteis. U. Campidonico, A Cardillo, C. Crisci. G. Medici, L. Piscitelli.
G. Salzillo. S. Stefanelli. S. Suriya).
Asti (G. Zola, C.A. Caratti. A. Buscemi. M. Alfani. M.L. Arnerio.
M. Bocchiardo, C. Birlocchio, A. I)' Anelli).
Augusta (P. Ferraguto. G. Passunisi).
A~t'lIino (D. Rotiroti. L. Marino).
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Bari "Vi Venere" (P. Ginevrino. F. Rorna , L. Taur ino, O. Pierfelice ,
R. Caroli . T . Conte. F. Ganimede , M. Russo, G . Sca lera . N. D'Arnato,
C. Altamura. M. Palella ) .
Barl " Policlinico" (L. Colon na, E. Fino , E. Crisrallo, I. De Luca.
G. Cas te llanetta . F. Bovenzi ).
Barletta (D. Messina, F. Cappabianca, G . Sarcina . G. Losappio , L.
Schieralli, P. Marzccc a).
Rassano del Grappa (F . Cucchini, M. Baggio),
BeHuno (G . Catania, A. Zerbi o).
Bergamo (A. Casa ri, M. Quaurociocch i, G. lnvernizzi ).
8ielIa (T. Alban o. F. Bobb a, D. Torta).
Bologna " Maggiore" (D . Bracchetti, D. Brunelli).
Bologna "S. Orsola-Malpighi" (A . Balboni. R. Cantore , F. Cice-
rone, C . Frondin i. G . Scaramuzz ini).
Bolzano (E . Braito, W. Lintner) .
Bnrgosesia (G . Tirella, F. Forni) .
Bovolnne (R. Scola Gagliardi, L. Bighignoli) .
Breno (F. Glisenti, G. Srraneo).
Brescia (E. Bonaldi, C. Cuccia , P. GeL N. Pagnoni. S. Rival.
Brindisi (A. Verrienti, A. Storelli, C. Andriulo , M. De Giorgi, A.N .
De Giorgio , V. Gallone, M. Guadalupi , O. Lupis, S. Nadovezza, A.
Tarcntini, A. Valzano).
Busto Arsizio (V . De Petra, E. Cecchetti. R. Scervino , P. Sola. G .C.
Ta bacchi, S . Tredic i, A. Medici ).
Cagliari " S . Michele" (A. Sanna, P. Maxia).
Caltagirone (5 . Mangiameli , D. Malfitano, G. Vi Stefano).
Casarano (G . Pettin ati , S. Monsellato . A.F . Portonc , A.S . Ciricugno.
M. leva).
Caser ta (E. Correale , G .c. Corsin i).
Campobassu (V . Centriuo , F. Baldi ni . C. De Vincenzo , F. Cocucci).
Castelfranco Veneto (c. Cernetti, L. Suzzi),
Castel San Giovanni (L. Maj, G . Achilli. L. Casaroli, F. Rizzi).
Catania " Ascoli Tomaselli" (V. Tirnpanaro).
Catania " Generale" (A. Fiscella , R . Evola , R. Coco. F. Lisi ,
),'1. L. Barbagallo . G. Centamore . V. Bulla, A. Coppola. M. Franco, F.
Liberti, L. Vasquez. D. Castell i, R. Russo , A. Galass i).
Cento (A . Albert i. G.e. Carini ).
Cernusco Sui Naviglio (L. Prina , C . De Pont i).
Cesena (P. Acito, F. Busi, P.e. Ceru bini, G . Vella Vittoria, S . Euseb i,
S. Gherardi , R. l.ucchi, M. Mambell i, G . Manzoni, P.L. Pier i).
Chiari (c. Bellet, L.B . Bozz i).
Chieti (A . Rossi, e. Ciglia),
Cittadella (F. Cappelletti, R. Bruncati, R. Carlon. P. Maiolino).
Citta' di Castello (D. Niccolini. R. Giannin i, R. Tettamanti, G. Gam-
beri, G. Arcuri . S. Misuri, V. Do).
Codogno (G . Capretti, C. Marinoni ).
Collcferrn (5. Sonnino, M. Pagllei , M. Mariani, R. Lemme).
Como (G . Ferrari. S. Zerboni. H. Ce leste . W. Bonini) .
Cosenza " Civile " (F. Plastina . N. Venneri).
Cosenza "Inrca" (e. Vercillo , A. Pesola ).
Cremona (c. Emanuelli , M . Riboldi ).
Cuneo (N. De Benedi ctis, e. Bruna).
Desenzano del Garda (B. Lornanto . V. Ziacch i).
Eboli (5 . Baldi . F. Giovine).
Faenza (L. Pirazzini , D.M . Fischer , C . Finzi , A. Patroncini, R.
Casa nova) .
Ferrara (A. Pradell a , A. Masoni ).
Fidenza (E . Clari zia , S. Ferrante, P. Dascola, L. Bastoni , S . Calle gari .
L. Andreoli ).
Flrenze (E. Tadd eucci ).
1'02g1a (D. De Matteis. A. Di TaranlO).
Foligno (L. T ini Brunozzi. L. l\oleniconi).
Gallarate (G . Piva , R. Di Michele, R. Canl iani . F. Arancio . G.
Bardon , P. Bertoni, :\-1. Carucci, V. Denna, L Fossa. e. Tosetto ).
Galllpoli (N. Caputo. L. Stella. C. Fortunalo . C. Sch irinzi , E.M .
Pellegrino , P. Rom ano).
Garbagnate Milanese (L. Muzio. M. Rota Baldini ).
Genova "San Martino" (E. Cort i. R . Delfino . V. Marino . E.
Oldoino. M. Ronzitti , S . Rossi , P. Rossi. G. Sartori , A. Zoccola) .
Genova "Sampierdarena" (S . De Michcli s, V. Seu. S. Livi).
Giarre (G . Garaffo, S. Scandurra, V. Magnano, S. Manzoni, G.
Leonardi , C . Maugeri. G. La Rocca , F. Papa).
Giulillnuva (A. Pennesi, A. Ruggeri, G . Di Cio, T. Strangi, G . Lom-
bardi).
Gorizia (L. Bertolo, L. Slompi.
Grosseto (N. Svetoni, T . Lanzetta . D. D' Alonzo).
Grottaglie (e. Forleo, V. Portulano).
Guastalla (G . Bellodi . L. Veneri) .
Jesi (f . Racco, S . Gan zetti) ,
Imperia (M. De'Thomatis, R. Gallesio).
lsernia (D . Ricci. G. Evangel ista, U. Di Giacomo . P. Lemme, P.M .
Morgantini, e. Carrino, V. Mazza) .
Ivrea (G . Aquarn , M. Pavia, D. Bajard i. E. Chiappa , P. ldon e, P.
Musso , G. Possavino, A. Ravera).
Larnezia Terme (A. Scopelliti, A. Butera, G . Fcrlaino).
L' Aquila (P. Marsili , G . Castellani).
Latina (B . De Pasqual e, P. Gelfo l.
Lavagna (A . Bcrtulla. P. Rossell i).
Leece IM.R. Greco, A.M. Fazio ).
Lecco (V. Locatelli. P.F . Ravizza ).
Legnago (F. Barbaresi, G . Sgalambro).
Legnano (V. Baldrighi, G. Baldrighi, F. Passoni, L. Aiazzi, F. Ca-
fiero, C. Castelli, 0.1-'. Forzani, T. Forzani, L. Ronzoni, L. Turcato, G .
Sevesol,
Lucca (M . Lazzari).
Lugo (F. Capucci, E. Tampierij.
Magenta (A. Maggi , D. Dubini).
Mantova (M. Piva, I. Vandea).
Matera (V. Contuzzi. T . Scandiffio).
Melegnano (G. Colombo. F. Fot i).
Merate (E. Gola. F. Casellato ).
Mercogliano (G . Mottola . A. Tesorio ).
Messina (F. Con solo. F. Arrig o. G. Ore to , G . Cavalli ).
Milano " Nigua rd a-De Gasperis" lP .A. Merlin i).
Milano " Nigua rd a-Rizzi" (c. Fnppoli , N. Giutlice ).
Milano "Policlinico" (F. Ambrosini. G . Eriano).
Milano "San Carlo" (M. Morpurg o, M. Bossi . A. Masa, M. Pogna) .
Milano "San Paolo" (M . Gioventu ' , A. Verzuni ).
Milanu " Vialba-I. . Sacco" (M . Garimoldi , R. Sala).
Miranu (E. Piccolo, G. Zuin) .
Mod ena (W. Garuti , C. Bernard i).
Monfalcone (M. Palmier i, G . Zilio ).
Mon~a (F. Valagus sa , A. Rovati).
Napoli "Ascalesi" (G . Granato Corig liano, R. Santamaria) .
Napoli "Cardarelli" (V . Eliseo e Collabora tori).
Napoli "110 Policlinico-Ia Clinica Medica" (M. Condorelli, D. Bon-
uduce),
Napoli "Monaldi" (N. Mininni, Dr. R. Greco . S. Wolff. S. Severino.
M. Schiauarella. S. Siciliano . L. Violini}.
Napoli "II" Policlinico-Sez. Carrlioangiologia" (0. De Divitii s. M.
Pel itto).
:'IIapoli " San Paolo" (L. Nappi . M. Blasich, P.F . de Luca , F.
Espos itu, P. Ferraro , A. Munciello , G. Pezzell a, V. Piedimonte , G. Ros-
sano. O. Saffioni , F. Schiraldi, D. Di Cesare) ,
Nettuno (M. Mostacci , e. Biscont i).
Nuoru (M. Pittalis , V. Mureddu).
Parlova (S. Dalla Volta, F. Maddalen a).
Palermo "Cervello" (E . Geraci . A. Canonico, L. di Gregor io , F.
Giam brone) .
Palermo "Villa Sofia" (N. Sanfilippo , L. La Calce , A . Di Benedetto).
Paola ( I' . Bencardino , E. Perrotta. M. Sciamrnarclla , e. Fera, S.
Stancato. P. Lo Presti, T. Lupi, O. Caparello),
Parma (G. Botti . L. Favaro).
J'avia (l. A. Salerno, C. Panciroli. M. Ch illlicnli, M. Previt ali. P.
Bobba).
Perugia (P. Solinas. E. Chiuini).
"escara (E. D'Annunzio. G. Rasett i).
Pesda (E. Nannini, N. R. Peti x).
Piacen~a (U. Gazzola . G . Dieci . S. Arruzzoli . Ci.() . Villani. A. Gan-
doltini. A. Rosi).
Pietra Ligllre (M. Mellin i. L. Madruaa).
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